Mostrar el registro sencillo del ítem

dc.contributor.authorEspinosa, Miguel Ángel Cuesta
dc.contributor.authorMartín, Ana Bravo
dc.contributor.authorRodriguez-de las Parras, Esperanza 
dc.contributor.authorIglesias Nuñez, Nuria
dc.contributor.authorRamírez-Olivencia, German
dc.contributor.authorLago-Nuñez, Mar
dc.contributor.authorPuente-Puente, Sabino
dc.date.accessioned2020-02-12T12:23:47Z
dc.date.available2020-02-12T12:23:47Z
dc.date.issued2014-01
dc.identifier.citationInt J Infect Dis. 2014 Jan;18:32-7.es_ES
dc.identifier.issn1201-9712es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9081
dc.description.abstractThe objective of this study was to assess the epidemiological, laboratory, and clinical features of imported strongyloidiasis in a tropical medicine referral unit in Madrid, Spain.This was a retrospective study based on a review of medical records. A patient was diagnosed with strongyloidiasis when the infection could be detected by conventional stool analysis and/or serology against Strongyloides stercoralis, regardless of the presence of symptoms. RESULTS: One hundred and seventy-eight cases of strongyloidiasis were included in the study. Stool tests were performed in all patients, and serology in 160 patients (89.9%). The diagnosis of strongyloidiasis was based on serology only in four patients; 21 patients only had positive stool tests. A third of the total strongyloidiasis cases in this study were travel-related, mainly associated with short trips (<2 months). Only 47.8% of total cases were symptomatic. We found no differences in clinical presentation between immigrants and travelers with strongyloidiasis. CONCLUSIONS: Not only should strongyloidiasis be suspected in symptomatic travelers and immigrants, but it should also be ruled out when elevated IgE levels or eosinophilia are present. Strongyloidiasis can be asymptomatic in HIV patients, but it should be diagnosed and treated before a possible hyperinfection develops.es_ES
dc.description.sponsorshipThis study was supported by RICET RD06/0021/0003 ISCIII-RETICS. Ethical approval: The study was approved by the institutional ethics committee (GER-STR.201201).es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHIVes_ES
dc.subjectHelminthes_ES
dc.subjectStrongyloideses_ES
dc.subjectTraveles_ES
dc.subject.meshAdult es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshAsymptomatic Diseases es_ES
dc.subject.meshEmigration and Immigration es_ES
dc.subject.meshEosinophilia es_ES
dc.subject.meshFeces es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHumans es_ES
dc.subject.meshImmunoglobulin E es_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshRetrospective Studies es_ES
dc.subject.meshSpain es_ES
dc.subject.meshStrongyloides stercoralis es_ES
dc.subject.meshStrongyloidiasis es_ES
dc.subject.meshTravel es_ES
dc.titleImported strongyloidiasis in Spaines_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID24211226es_ES
dc.format.volume18es_ES
dc.format.page32-7es_ES
dc.identifier.doi10.1016/j.ijid.2013.09.009es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1878-3511es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.ijid.2013.09.009es_ES
dc.identifier.journalInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseaseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD06/0021/0003 ISCIII-RETICSes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional